SCHEMBL3016315

SCHEMBL3016315

COc1ccc(S(=O)(=O)C2CCN(c3nc(-c4ccc(C)cc4)cs3)CC2)c(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.53
RAB9A P51151 5/20 0.53
MAPT P10636 10/20 0.52
NPC1 O15118 4/20 0.51
LMNA P02545 6/20 0.51
TDP1 Q9NUW8 1/20 0.51
ALDH1A1 P00352 6/20 0.48
HTT P42858 3/20 0.47
POLB P06746 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAPK1 P28482 4/20 0.45
USP2 O75604 3/20 0.43
HSD17B10 Q99714 2/20 0.43
TP53 P04637 2/20 0.43
RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007225 0.95 SMN1; SMN2 (0.58) SMN1; SMN2RAB9AMAPTNPC1LMNA
SCHEMBL3010353 0.93 SMN1; SMN2 (0.48) SMN1; SMN2RAB9AMAPTNPC1LMNA
SCHEMBL3015674 0.93 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AMAPTNPC1LMNA
SCHEMBL3008140 0.92 RAB9A (0.52) SMN1; SMN2RAB9AMAPTNPC1LMNA
SCHEMBL3017084 0.92 MAPT (0.57) SMN1; SMN2RAB9AMAPTNPC1LMNA
SCHEMBL2999403 0.91 SMN1; SMN2 (0.49) SMN1; SMN2RAB9AMAPTNPC1LMNA
SCHEMBL3014374 0.91 SMN1; SMN2 (0.57) SMN1; SMN2RAB9AMAPTNPC1LMNA
SCHEMBL3014942 0.91 SMN1; SMN2 (0.50) SMN1; SMN2RAB9AMAPTNPC1LMNA
SCHEMBL3016498 0.90 MAPT (0.49) SMN1; SMN2RAB9AMAPTNPC1LMNA
SCHEMBL3002158 0.90 SMN1; SMN2 (0.51) SMN1; SMN2RAB9AMAPTNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.